Targeting of C-ROS-1 Activity Using a Controlled Release Carrier to Treat Craniosynostosis in a Preclinical Model of Saethre-Chotzen Syndrome

Figure 1

In vitro dissolution profile of the formulated CMC microdisks. (a) Heatmap diagram of the microdisks dissolution. Diagrams show the absorbance intensity measured in an area of 1 cm². The Brilliant Blue G drug surrogate model contained in the microdisks releases at the synthetic scalp and diffuses between the skin-bone space along time. (b) Brilliant blue G release profile of the formulated microdisks. (c) Increment of the microdisks diffusion area along time. Data represented as the mean ± SD (n = 5–12 replicates per time point).

(a)

(b)

(c)